

OK to Enter /SNM/

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-2 (canceled).

3. (currently amended): A method for screening a compound for development of a drug ~~for the treatment of Alzheimer's disease~~, said method comprising:

(a) culturing a neuron expressing APP intracellular C terminal domains (AICD) and p53 in a culture medium that is supplemented with cisplatin, wherein said neuron is cultured (i) in the presence of a ~~candidate~~ compound and (ii) in the absence of the ~~candidate~~ compound, respectively, ~~to give cultured neurons~~;

(b) homogenizing the neuron obtained in step (a) ~~cultured neurons~~ to form a cell lysate,

(c) contacting the cell lysate with a first antibody, to form an AICD/p53/first antibody immune complex, wherein said first antibody is selected from the group consisting of an anti-AICD antibody and an anti-p53 antibody,

(d) detecting and quantifying the AICD/p53/first antibody immune complex from step (c),

OK to Enter /SNM/

(e) comparing the amount of the AICD/p53/first antibody immune complex formed in the absence of the ~~eandidate~~ compound with the amount of the AICD/p53/first antibody immune complex formed in the presence of the ~~eandidate~~ compound, and

(f) selecting the ~~eandidate~~ compound that decreases the amount of the AICD/p53/first antibody immune complex compared to the amount of the AICD/p53/first antibody immune complex formed in the absence of the compound, wherein said decrease in the amount of the AICD/p53 complex is indicative of the compound inhibiting binding between AICD and p53.

4-12. (canceled).

13. (previously presented): The method according to claim 3, wherein the step (d) is conducted by contacting the AICD/p53/first antibody immune complex with a second antibody, wherein the second antibody is selected from an anti-AICD or an anti-p53 antibody and is different from the first antibody.

14. (new): The method according to claim 3, wherein said compound is selected from the group consisting of nucleic acid, protein, high molecular weight compound, and low molecular weight compound.